LER & CER: letter to Editor Rheumatology

Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.

E. Duran¹, B.E.S. Yildirim², Ö. Karadağ³

Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey. docemineduran@gmail.com
Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey.

CER14777
2023 Vol.41, N°9 ,Suppl.135
PI 0008
LER & CER: letter to Editor Rheumatology

Free to view
(click on article PDF icon to read the article)

PMID: 34494954 [PubMed]

Received: 04/05/2021
Accepted : 09/07/2021
In Press: 07/09/2021
Published: 27/09/2023